Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in Xencor, Inc. (NASDAQ:XNCR – Get Rating) by 5.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,977 shares of the biopharmaceutical company’s stock after purchasing an additional 585 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Xencor were worth $285,000 as of its most recent SEC filing.
Several other institutional investors have also recently made changes to their positions in the stock. Baillie Gifford & Co. lifted its position in shares of Xencor by 4.6% during the third quarter. Baillie Gifford & Co. now owns 32,055 shares of the biopharmaceutical company’s stock worth $833,000 after acquiring an additional 1,398 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Xencor by 63.2% in the third quarter. Allspring Global Investments Holdings LLC now owns 6,546 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 2,536 shares in the last quarter. Louisiana State Employees Retirement System bought a new position in Xencor in the third quarter valued at $740,000. Everence Capital Management Inc. bought a new position in Xencor in the third quarter valued at $218,000. Finally, ExodusPoint Capital Management LP bought a new position in Xencor in the second quarter valued at $404,000. Hedge funds and other institutional investors own 98.99% of the company’s stock.
Wall Street Analyst Weigh In
A number of research analysts have recently issued reports on XNCR shares. StockNews.com raised Xencor from a “sell” rating to a “hold” rating in a research note on Monday, November 14th. Royal Bank of Canada cut their target price on Xencor from $40.00 to $36.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 8th. Cowen began coverage on Xencor in a research note on Tuesday, December 6th. They issued an “outperform” rating on the stock. Canaccord Genuity Group cut their target price on Xencor from $50.00 to $48.00 in a research note on Wednesday, November 9th. Finally, Raymond James raised Xencor from an “outperform” rating to a “strong-buy” rating and set a $58.00 target price on the stock in a research note on Thursday, October 13th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $47.50.
Xencor Stock Performance
Xencor (NASDAQ:XNCR – Get Rating) last released its earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.22. The firm had revenue of $27.30 million during the quarter, compared to analyst estimates of $15.33 million. Xencor had a net margin of 10.07% and a return on equity of 4.04%. As a group, sell-side analysts forecast that Xencor, Inc. will post -1.61 earnings per share for the current fiscal year.
Insider Activity at Xencor
In related news, CMO Allen Yang sold 3,737 shares of the firm’s stock in a transaction that occurred on Monday, December 19th. The shares were sold at an average price of $27.00, for a total transaction of $100,899.00. Following the completion of the sale, the chief marketing officer now owns 63,521 shares of the company’s stock, valued at $1,715,067. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.23% of the stock is owned by insiders.
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
- Get a free copy of the StockNews.com research report on Xencor (XNCR)
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.